Biomarkers and assays for carcinogenesis

Abstract

The present invention relates to carcinogenesis biomarkers produced by phenobarbitol-treated rat hepatocytes, nucleic acid molecules that encode carcinogenesis biomarkers or a fragment thereof and nucleic acid molecules that are useful as probes or primers for detecting or inducing carcinogenesis, respectively. The invention also relates to applications of the factor or fragment such as forming antibodies capable of binding the carcinogenesis biomarkers or fragments thereof.

1 - 24 . (canceled)  
     
     
         25 . A method for determining a level or pattern of a carcinogenesis biomarker in a cell comprising: 
 (a) incubating, under conditions permitting specific nucleic acid hybridization, a marker nucleic acid molecule, said marker nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ NO:1 through SEQ NO:580 or complements thereof, with a nucleic acid molecule obtained from said cell, wherein nucleic acid hybridization between said marker nucleic acid molecule, and said complementary nucleic acid molecule obtained from said cell permits the detection of said carcinogenesis biomarker;    (b) permitting hybridization between said marker nucleic acid molecule and said complementary nucleic acid molecule obtained from said cell; and    (c) detecting the level or pattern of said complementary nucleic acid, wherein the detection of said complementary nucleic acid is predictive of the level or pattern of said carcinogenesis biomarker.    
     
     
         26 . The method of  claim 25 , wherein said level is predictive of said carcinogenesis biomarker.  
     
     
         27 . The method of  claim 25 , wherein said pattern is predictive of said carcinogenesis biomarker.  
     
     
         28 . The method of  claim 25 , wherein said level or pattern is detected by in situ hybridization.  
     
     
         29 - 30 . (canceled)  
     
     
         31 . A method for measuring the carcinogenicity of a composition comprising: 
 (a) culturing a cell line;    (b) exposing said cell line to said composition; and    (c) determining the presence or absence of mRNA which substantially hybridizes to at least one nucleic acid sequence selected from the group consisting of SEQ NO:1 through SEQ NO:580 and complements thereof.    
     
     
         32 . A method for measuring the carcinogenicity of a composition comprising: 
 (a) exposing a cell, tissue sample, or test animal to said composition; and    (b) determining the presence or absence of mRNA which substantially hybridizes to an at least one nucleic acid sequence selected from the group consisting of SEQ NO:1 through SEQ NO:580 and complements thereof.    
     
     
         33 . The method of  claim 32 , wherein said mammal is a rat.